Global Coalition For Adaptive Research Inc
- Assets
- $59.6m
- Revenue
- $28.8m
- Investments
- $8.9m
- Employees
- 36
- Location
- Larkspur, CA
- Founding
- 04/2018
- Data as of
- 12/2023
- EIN
- 82-1199380
Organization Overview
Global Coalition For Adaptive Research Inc is located in Larkspur, CA. The organization was established in 2018. According to its NTEE Classification (H48) the organization is classified as: Brain Disorders Research, under the broad grouping of Medical Research and related organizations. As of 12/2023, Global Coalition For Adaptive Research Inc employed 36 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Global Coalition For Adaptive Research Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF CURES FOR PATIENTS WITH RARE AND DEADLY DISEASES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT (GBM AGILE), GCAR'S INITIAL AND MOST ADVANCED INITIATIVE, IS A GLOBAL PHASE 2/3 ADAPTIVE PLATFORM TRIAL, DESIGNED TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR GLIOBLASTOMA OVER TIME IN AN EFFORT TO IMPROVE PATIENT OUTCOMES. GBM AGILE HAS BEEN OPEN AND ENROLLING PATIENTS SINCE JULY 2019 WITH OVER 1,900 PATIENTS SCREENED TO DATE. IN 2023, SEVERAL PUBLICATIONS /PRESENTATIONS WERE CONDUCTED TO PRESENT DATA AND LATEST PROGRESS TO THE RESEARCH COMMUNITY, INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY, AND THE SOCIETY FOR NEURO-ONCOLOGY. ADDITIONALLY, GCAR PROVIDES ON-GOING SUPPORT TO THE GBM RESEARCH AND CLINICAL COMMUNITY THROUGH PHILANTHROPIC DONATIONS TO ADVOCACY GROUPS, AS WELL AS EDUCATION, OUTREACH AND CLINICAL COMMUNITY ENGAGEMENT. TO PROMOTE BRAIN CANCER AWARENESS IN 2023, GCAR PARTICIPATED IN ADVOCACY PARTNER FUND RAISING EVENTS, PANEL DISCUSSIONS, AND ACADEMIC CONFERENCES. NOTABLE HIGHLIGHTS INCLUDED RINGING THE NASDAQ CLOSING BELL ALONGSIDE PATIENTS, ADVOCACY PARTNERS, AND PHARMACEUTICAL PARTNERS TO PROMOTE BRAIN TUMOR AWARENESS MONTH AND PARTICIPATING IN THE WHITE HOUSE CANCER MOONSHOT FORUM ON BRAIN CANCER.
PROGRAMS IN DEVELOPMENT. ADDITIONAL EFFORTS ARE FOCUSED ON ACTIVITIES TO SUPPORT THE LAUNCH, DESIGN, EDUCATION, OUTREACH, AND CLINICAL COMMUNITY ENGAGEMENT FOR MULTIPLE PROGRAMS IN DEVELOPMENT INCLUDING BILIARY TRACT CANCER, OVARIAN CANCER, NEUROFIBROMATOSIS, AND PANCREATIC CANCER, ALL RARE AND DEADLY DISEASES WITH CRITICAL NEED FOR FURTHER DEVELOPMENT OF NEW TREATMENT OPTIONS FOR PATIENTS.1 SMALLER FEDERAL PROGRAM TO SUPPORT COVID RESEARCH WAS IN WIND-DOWN STAGE IN 2023 (ENDED FEBRUARY 2024).
REMAP-COVID, A SUB-STUDY OF REMAP-CAP (A RANDOMIZED, EMBEDDED, MULTIFACTORIAL, ADAPTIVE PLATFORM TRIAL FOR COMMUNITY-ACQUIRED PNEUMONIA), WAS DEVELOPED TO TEST MULTIPLE INTERVENTIONS FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH COVID-19. GCAR SPONSORED REMAP-COVID IN THE US, WITH THE UNIVERSITY OF PITTSBURGH AS THE US REGIONAL COORDINATING CENTER. PARTNERING WITH ACADEMIA, INDUSTRY AND MULTIPLE HEALTHCARE SYSTEMS, OVER 500 PATIENTS WERE RANDOMIZED WITHIN FOUR DOMAINS IN THE US. WITH THE PANDEMIC WINDING DOWN, THE TRIAL WAS CLOSED IN JUNE 2023. IN 2023, 2 CLINICAL STUDY REPORTS WERE SUBMITTED TO THE AGENCY AND 4 KEY PUBLICATIONS WERE PRESENTED VIA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, NEW ENGLAND JOURNAL OF MEDICINE, AND INTENSIVE CARE MEDICINE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Sujuan Ba PHD Director | Trustee | 2 | $0 |
Brian Alexander MD MPH Director | Trustee | 2 | $0 |
Faramarz Yousefzadeh JD Llm Chairman Of The Board | Trustee | 5 | $0 |
Gary Gordon MD PHD Senior Medical Advisor And Director | Trustee | 16 | $180,000 |
John Frishkopf Mms Director | Trustee | 2 | $0 |
Timothy Cloughesy MD Chief Medical Officer And Director | OfficerTrustee | 16 | $180,000 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Iqvia Clinical Research | 12/30/23 | $20,504,461 |
Medqia Clinical Research | 12/30/23 | $218,115 |
Medidata Clinical Research | 12/30/23 | $346,882 |
Wilson Sonsini Goodrich & Rosati Legal Services | 12/30/23 | $159,964 |
Berry Consulting Llc Statistical Consultation | 12/30/23 | $130,705 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $3,081,228 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $3,081,228 |
| Total Program Service Revenue | $23,964,880 |
| Investment income | $1,733,052 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $28,779,160 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $1,152,500 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $5,500 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $2,793,407 |
| Compensation of current officers, directors, key employees. | $907,758 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $2,717,893 |
| Pension plan accruals and contributions | $48,053 |
| Other employee benefits | $302,420 |
| Payroll taxes | $282,254 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $165,468 |
| Fees for services: Accounting | $37,890 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $61,318 |
| Fees for services: Other | $21,478,344 |
| Advertising and promotion | $16,694 |
| Office expenses | $36,287 |
| Information technology | $119,838 |
| Royalties | $0 |
| Occupancy | $15,794 |
| Travel | $251,271 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $69,027 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $156,669 |
| All other expenses | $0 |
| Total functional expenses | $29,710,627 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $3,206,238 |
| Savings and temporary cash investments | $1,546,512 |
| Pledges and grants receivable | $1,079,637 |
| Accounts receivable, net | $2,040,738 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $2,848,349 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $40,029,401 |
| Investments—other securities | $8,859,855 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $59,610,730 |
| Accounts payable and accrued expenses | $6,428,918 |
| Grants payable | $0 |
| Deferred revenue | $11,938,542 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $1,250,000 |
| Total liabilities | $19,617,460 |
| Net assets without donor restrictions | $39,993,270 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $59,610,730 |
Grants Awarded
Over the last fiscal year, Global Coalition For Adaptive Research Inc has awarded $1,150,000 in support to 3 organizations.
| Grant Recipient | Amount |
|---|---|
CHOLANGIOCARCINOMA FOUNDATION PURPOSE: CLINICAL TRIAL SUPPORT | $150,000 |
NATIONAL FOUNDATION FOR CANCER RESEARCH PURPOSE: CLINICAL TRIAL SUPPORT | $500,000 |
AIM-HI ACCELERATOR FUND INC PURPOSE: CLINICAL TRIAL SUPPORT | $500,000 |